We are live on
!
Find out more
CCM
Catapult Capital Management Portfolio holdings
AUM
$265M
1-Year Est. Return
21.83%
This Fund
S&P 500
This Quarter
Est. Return
-6.98%
1 Year Est. Return
+21.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$265M
AUM Growth
-$431M
(-62%)
Cap. Flow
-$403M
Cap. Flow
% of AUM
-152.44%
Top 10 Holdings %
Top 10 Hldgs %
27.43%
Holding
286
New
68
Increased
19
Reduced
60
Closed
135
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$9.98M |
| 2 |
NUVA
NuVasive, Inc.
NUVA
|
+$4.39M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$3.85M |
| 4 |
Boston Scientific
BSX
|
+$3.16M |
| 5 |
Pfizer
PFE
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$16M |
| 2 |
AbbVie
ABBV
|
+$15.9M |
| 3 |
Zoetis
ZTS
|
+$13.5M |
| 4 |
PepsiCo
PEP
|
+$12.8M |
| 5 |
McKesson
MCK
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.36% |
| 2 | Consumer Discretionary | 7.36% |
| 3 | Industrials | 6.49% |
| 4 | Technology | 4.09% |
| 5 | Financials | 3.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $11.6M | 4.37% |
42,500
+32,500
| +325% | +$9.98M |
|
2
Edwards Lifesciences
EW
$50B
| $9.03M | 3.42% |
381,258
-344,460
| -47% | -$8.31M |
|
|
3
Zoetis
ZTS
$31.9B
| $8.05M | 3.04% |
195,525
-291,140
| -60% | -$13.5M |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $7.97M | 3.01% |
72,877
+22,877
| +46% | +$2.64M |
|
|
CNW
5
PUT
DELISTED
CON-WAY INC.
CNW
| $6.64M | 2.51% |
+140,000
| New | +$5.49M |
|
|
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
| $6.51M | 2.46% |
135,000
+85,000
| +170% | +$4.39M |
|
7
CALL
Bank of America
BAC
$433B
| $6.23M | 2.36% |
+400,000
| New | +$6.73M |
|
8
DaVita
DVA
$15.3B
| $6.14M | 2.32% |
84,938
-90,162
| -51% | -$6.99M |
|
|
9
Boston Scientific
BSX
$68.4B
| $5.5M | 2.08% |
335,000
+185,000
| +123% | +$3.16M |
|
10
AtriCure
ATRC
$2.04B
| $4.93M | 1.86% |
225,000
+15,000
| +7% | +$375K |
|
11
CALL
Magna International
MGA
$19B
| $4.8M | 1.81% |
+100,000
| New | +$5.17M |
|
12
Universal Health Services
UHS
$9.88B
| $4.75M | 1.8% |
38,095
-51,905
| -58% | -$7.22M |
|
|
ALR
13
DELISTED
Alere Inc
ALR
| $4.41M | 1.67% |
91,622
+41,622
| +83% | +$2.16M |
|
|
14
CVS Health
CVS
$134B
| $4.36M | 1.65% |
45,172
-151,775
| -77% | -$16M |
|
|
CCRN
15
DELISTED
Cross Country Healthcare
CCRN
| $3.74M | 1.41% |
275,000
+25,000
| +10% | +$340K |
|
16
Gilead Sciences
GILD
$163B
| $3.58M | 1.35% |
36,408
-34,392
| -49% | -$3.82M |
|
17
CALL
Agilent Technologies
A
$39.2B
| $3.43M | 1.3% |
100,000
+70,000
| +233% | +$2.65M |
|
18
Align Technology
ALGN
$12.4B
| $3.39M | 1.28% |
59,722
-20,278
| -25% | -$1.21M |
|
|
MNK
19
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $3.2M | 1.21% |
+50,000
| New | +$4.95M |
|
20
CALL
AB InBev
BUD
$166B
| $3.19M | 1.21% |
30,000
+15,000
| +100% | +$1.74M |
|
|
21
Vertex Pharmaceuticals
VRTX
$122B
| $3.12M | 1.18% |
+30,000
| New | +$3.85M |
|
22
McDonald's
MCD
$191B
| $3.06M | 1.15% |
31,007
-35,193
| -53% | -$3.43M |
|
23
PUT
Molson Coors Class B
TAP
$7.79B
| $2.91M | 1.1% |
+35,000
| New | +$2.53M |
|
|
BCR
24
DELISTED
CR Bard Inc.
BCR
| $2.9M | 1.09% |
+15,537
| New | +$2.94M |
|
|
25
Pfizer
PFE
$142B
| $2.82M | 1.07% |
+94,657
| New | +$3.04M |
|
Similar funds
LOCB
AF
TCOTO
DCM
SCA
LPVHS
ATC
TFF
Catapult Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Catapult Capital Management held 286 positions worth $265M, down 62% from $696M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Catapult Capital Management withdrew a net $403M in Q3 2015, closing 135 positions and reducing 60 holdings. Its most notable exit was PepsiCo, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 43% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Catapult Capital Management opened a new position in Vertex Pharmaceuticals worth $3.12M.
- Catapult Capital Management's largest Q3 2015 buy was Vertex Pharmaceuticals: 30,000 shares worth $3.12M.
- Catapult Capital Management added most to Allergan plc in Q3 2015, an estimated $9.98M increase.
- Catapult Capital Management's biggest Q3 2015 reduction was CVS Health, cutting an estimated $16M.
- Catapult Capital Management fully exited PepsiCo in Q3 2015, selling an estimated $12.8M.
- Catapult Capital Management's ten largest holdings make up 27% of its $265M portfolio in Q3 2015.
- Catapult Capital Management opened 68 new positions and closed 135 in Q3 2015.
- Catapult Capital Management's portfolio value fell 62% quarter-over-quarter to $265M.
Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.